BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Investment analysts at Wedbush upped their FY2020 EPS estimates for BioMarin Pharmaceutical in a research report issued on Monday. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will post earnings of $1.52 per share for the year, up from their prior estimate of $1.42. Wedbush has a “Outperform” rating and a $110.00 price objective on the stock. Wedbush also issued estimates for BioMarin Pharmaceutical’s FY2021 earnings at $2.53 EPS and FY2022 earnings at $5.14 EPS.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The firm had revenue of $358.31 million during the quarter, compared to analysts’ expectations of $346.24 million. BioMarin Pharmaceutical had a negative net margin of 8.91% and a negative return on equity of 3.18%.
Shares of BioMarin Pharmaceutical (NASDAQ BMRN) traded down $0.34 during mid-day trading on Wednesday, hitting $85.82. 575,878 shares of the stock traded hands, compared to its average volume of 1,353,818. The stock has a market capitalization of $15,130.00, a P/E ratio of -94.23 and a beta of 1.73. The company has a quick ratio of 2.12, a current ratio of 2.70 and a debt-to-equity ratio of 0.29. BioMarin Pharmaceutical has a fifty-two week low of $77.04 and a fifty-two week high of $100.51.
Several large investors have recently modified their holdings of BMRN. Rothschild Investment Corp IL acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth about $657,000. Eversept Partners LLC acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth about $4,075,000. Schwab Charles Investment Management Inc. increased its holdings in shares of BioMarin Pharmaceutical by 7.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 320,485 shares of the biotechnology company’s stock worth $29,828,000 after acquiring an additional 22,242 shares during the period. Wealthstreet Investment Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth about $988,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of BioMarin Pharmaceutical by 184.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,289 shares of the biotechnology company’s stock worth $293,000 after acquiring an additional 2,134 shares during the period.
In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 30,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $90.66, for a total transaction of $2,719,800.00. Following the sale, the executive vice president now directly owns 112,942 shares of the company’s stock, valued at $10,239,321.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elaine J. Heron sold 800 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $88.90, for a total transaction of $71,120.00. Following the sale, the director now directly owns 38,385 shares in the company, valued at $3,412,426.50. The disclosure for this sale can be found here. Insiders have sold 104,627 shares of company stock worth $9,314,362 over the last three months. 1.85% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “FY2020 Earnings Forecast for BioMarin Pharmaceutical Inc. (BMRN) Issued By Wedbush” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/03/14/fy2020-earnings-forecast-for-biomarin-pharmaceutical-inc-bmrn-issued-by-wedbush.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.